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The antihypertensive and diuretic effects of amiloride and 
of its combination with hydrochlorothiazide 
The hypotensive effect as well as changes in serum electrolytes and uric acid of amiloride 
(AM) and of its combination with hydrochlorothiazide (HC) were studied. In five hypertensive 
patients over a five-day period, AM and HC administered together produced more 
natriuresis than either alone. Potassium, chloride, and bicarbonate concentrations in the 
serum showed a smaller alteration from normal with the combination than with HC alone. 
Twelve additional outpatients with moderate hypertension were followed for twelve weeks 
with the use of randomized Latin squares in double-blind fashion. A blood pressure-lowering 
effect of AM by itself or when added to HC was not seen. AM had no discernible effect 
on serum glucose, uric acid, or chloride concentrations. 
Hermann Kampffmeyer, M.D., and James Conway, M.D., Ph.D. Ann Arbor, Mich. 
Department of Internal Medicine, University Hospital, The University of Michigan 
Medical Center 
Amiloride (AM), N-amidino-3,5,-diam-
ino-6-chloropyrazinamide hydrochloride, in-
duces natriuretic effects without potassium 
loss or rise in serum uric acid. 1 , 4 In single 
doses, AM has been shown to be less po-
tent than hydrochlorothiazide (He); how-
ever, when administered daily in approx-
imately maximal dosage, the natriuretic ac-
tion of AM is sustained for a longer period 
so that the negative sodium balance equals 
that of He after 5 days of administration. 5 
It seemed desirable therefore to investigate 
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the diuretic and hypotensive effect of AM 
combined with He. For this purpose, a 
short balance study was undertaken to 
measure the magnitude of the sodium ex-
cretion when He and AM were given to-
gether; then in an outpatient trial the anti-
hypertensive effect of each drug given 
separately was compared with the com-
bination. 
Methods 
Balance study. Five untreated patients 
with established hypertension, diastolic 
blood pressures between 100 and 130 mm. 
Hg, and no evidence of renal failure, 
edema, or symptoms of heart failure were 
studied in the Clinical Research Unit of 
this hospital. Sodium intake was 95 mEq. 
per day. Drugs were administered after 
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3 to 5 days of hospitalization, HC in a 
dosage of 50 mg. twice a day, and AM 
10 mg. twice a day. There was no restriction 
of water or potassium; no cathartics were 
given for 3 days prior to treatment. The 
collection of specimens and the analyses 
for the various parameters were as in our 
previous studies. 5 
Outpatient study. 
Experimental design. Twelve patients 
received AM (20 mg. per day) alone, HC 
( 100 mg. per day) alone, or a combination 
of both for a period of 3 weeks. These 
were randomized, 3 patients per group in 
four Latin squares. The trial was con-
ducted in double-blind fashion. The manu-
facturer had randomized and coded the 
drugs for the trial periods and labeled the 
bottles with patient numbers and period 
numbers. (> It was not necessary to break 
the code until the trial had been com-
pleted. The patients took one capsule and 
one tablet twice daily throughout the 
whole trial. Prior to receiving active drugs, 
each patient was given identically appear-
ing placebos for 3 weeks. During this pe-
riod, investigators (but not the patients) 
knew that the patients were receiving 
placebo. 
Patients ranging from 34 to 68 years 
in age already under treatment with HC 
for moderate established essential hyper-
tension were chosen. In none was there 
evidence of malignant hypertension or 
heart failure; blood pressure had not ex-
ceeded 200/130 mm. Hg. They had been 
trained by the clinic nurse to take their 
blood pressure at home and had reported 
reliable data for many months. They re-
corded body weight daily On rising. After 
an outline of this study had been discussed 
and an agreement had been obtained from 
the patient, the subjects received an in-
formation sheet explaining the trial in de-
tail. 
The trial. The trial took 12 weeks. At 
OSupplied by Dr. W. Wilkinson of Merck Sharp & 
Dohme, West Point, Pa. 
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the end of each trial period, a 24 hour 
urine sample was collected for creatinine 
and sodium determination. On the day of 
each visit in the outpatient department, a 
blood sample was drawn for analyses of 
serum N a, K, CI, creatinine, blood urea 
nitrogen, glucose, and uric acid concentra-
tions, as well as for hematological and 
liver function. The remaining tablets from 
the previous trial period were counted to 
establish whether the prescribed number 
had been taken, and the medication for the 
next period was given. The patients were 
provided with special forms on which they 
recorded morning blood pressure readings 
in recumbent and upright positions and 
body weights. To check the accuracy of 
the patients' readings, the nurse as well as 
the patient measured the blood pressure 
at each clinic visit. 
Analysis of the data. The data for the 
treatment period have been analyzed by 
the analYSis of variance for a group of 
Latin squares with a single value in each 
box. 3 The two degrees of freedom (d.f.) 
for treatments were broken down for or-
thogonal comparison6 : 1 d.f. for the com-
parison between AM and the other two 
treatments, and 1 d.f. for HC against the 
combination of AM and He. For the test 
of the Ho hypothesis on the home blood 
pressure, the mean values of the lying 
blood pressure in the morning over the last 
5 days of each period were entered into 
each box. 
The means obtained with the three dif-
ferent treatments were compared with one 
another and with placebo with the use of 
Duncan's Multiple Range Test with the 
standard error of the pooled variance of 
the four means.2 ObViously, the placebo 
period could not be included in the analy-
sis of variance. 
Results 
Balance study. The results are listed in 
Table 1. The values indicate the means on 
5 patients and the corresponding standard 
errors. On combined therapy over the 5-
day period, the natriuretic effect was 
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greater than that with either drug alone,5 
but after 3 days it was only slightly in ex-
cess of the dietary intake. The cumulative 
negative sodium balance calculated was 
378 mEq. (S.E. = ±26). The serum po-
tassium levels increased from 4.3 to 5.0 
mEq. per liter. Serum sodium fell, and the 
creatinine clearance also fell. The mean 
recumbent blood pressure fell from 178/ 
120 to 160/112 mm. Hg. 
Outpatient study. Data for this trial are 
listed in Table II. The mean change in 
systolic/diastolic blood pressures from 
placebo averaged 6/1 mm. Hg with AM, 
12/6 mm. Hg with HC, and 19/8 mm. Hg 
with the combination. With the Multiple 
Range Test used for comparison of blood 
pressures, there was a difference at the 5 
per cent level between the blood pressure 
on placebo (column 2) and treatment with 
the combination of AM and HC (column 
5). The mean body weight of 78.9 kilo-
grams on placebo fell 0.8 kilogram on 
AM, 1.3 kilograms on HC; and 2.7 kilo-
grams on the combination. 
The analysis of variance of blood pres-
sure showed differences among the treat-
ments (column 6). The blood pressure-
lowering effect of HC and the combina-
tion of HC and AM was greater than that 
of AM alone (column 7). The combination 
showed greater effect on systolic blood 
pressure than HC alone, but there was no 
significant effect on the diastolic blood 
pressure. The F-values obtained by ortho-
gonal contrast for the comparison between 
different treatments (columns 7 and 8) 
did not exceed the critical value on the 
5 per cent level. The analysis of variance 
showed no important differences between 
individuals or groups in the Latin squares 
or for consecutive time periods. 
After 3 weeks of therapy, serum potas-
sium levels were 4.7 mEq. per liter on AM, 
3.5 on HC, and 4.2 mEq. per liter on the 
combination; these differences among treat-
ments were significant. The serum sodium 
concentration was lower on the combina-
tion of HC and AM compared to HC 
alone. AM itself did not affect the serum 
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chloride concentration whereas HC alone 
and in combination with AM significantly 
lowered the chloride concentration. 
The serum creatinine and BUN concen-
trations were greater on the combination 
than on HC alone but were well in the 
normal range. 
HC alone or in combination with AM 
had more effect on serum glucose levels 
than AM alone. A similar trend was ob-
served with the serum uric acid. HC in-
creased the mean uric acid level by 1.2 
mg. per cent, whereas no increase was seen 
after AM. Creatinine excretion was not 
affected. 
Undesirable effects. There were no sub-
jective symptoms due to the drugs. Three 
weeks after treatment with AM and He 
in combination, one patient then receiving 
AM alone had an elevated serum glutamic 
oxalacetic transaminase (168 units). Four-
teen days later it had returned to 46 units. 
The patient had no subjective symptoms 
and subsequent values were normal. 
Discussion 
The blood pressures with He treatment 
before the trial were practically the same 
as those with He during the trial. 
AM alone had little effect on the blood 
pressure and the additional fall when AM 
was added to He was not clinically sig-
nificant. Thus AM, although previously 
shown to have as great an effect on so-
dium balance as He,5 appears to have in-
significant antihypertensive properties. This 
may be accounted for by the possibility 
that a substantial part of the sodium lost 
does not come from the extracellular fluid 
compartment, but may represent an ex-
change of sodium for cellular potassium. 
This was thought to be likely since the 
change in body weight and hematocrit for 
a given loss of sodium was smaller with 
AM than it was with He.5 AM is there-
fore of special interest as a diuretic since 
it may cause the withdrawal of sodium 
from compartments not usually affected by 
thiazide diuretics, which in special states 
of edema might be of practical importance. 
354 KampfJmeyer and Conway 
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